Non-alcoholic fatty liver disease (NAFLD) — now called metabolic dysfunction-associated steatotic liver disease (MASLD) — affects roughly 1 in 4 people globally. GLP-1 medications are showing remarkable results in reversing it.
The LEAN trial (liraglutide) and NASH trials with semaglutide showed liver fat reduction of 30–40% and significant improvement in liver histology. The SURMOUNT-4 extension showed tirzepatide producing some of the largest liver fat reductions ever recorded in a clinical trial.
Combine GLP-1 with liver-supportive habits: reduce alcohol, limit fructose (sugary drinks, fruit juice), eat more fiber, and maintain regular exercise. These amplify the drug's liver benefits.
Getting 100g+ of protein daily on a reduced appetite is hard. Strategic timing makes it more achievable — and more effective for muscle preservation.
Medication helps with appetite. But the mental skills for sustainable weight management — resilience, flexibility, self-compassion — must be built intentionally.
People who share their journey with a community — online or in person — consistently achieve better outcomes. Here's why, and where to find yours.